Seeking Alpha

Shares of Aeterna Zentaris (AEZS +13.2%) pop after being initiated with a Buy at Roth Capital...

Shares of Aeterna Zentaris (AEZS +13.2%) pop after being initiated with a Buy at Roth Capital with a price target of $1.75, more than double its current valuation. Roth cites optimism over its endometrial cancer candidate, AEZS-108, which plans to begin Phase III testing before the end of the year, the potential for its AEZS-130, an Adult Growth Hormone Deficiency diagnostic that the company is preparing for a New Drug Application.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs